Generic Name :
clorazepate dipotassium
Brand Name: Apo-Clorazepate
(CAN), Novo-Clopate (CAN), Tranxene-SD, Tranxene-SD Half Strength,
Tranxene-T-tab
Classification:
Benzodiazepine, Anxiolytic, Antiepileptic
Pregnancy Category
D
Controlled Substance C-IV
Controlled Substance C-IV
Dosage
& Route
Individualize dosage; increase
dosage gradually to avoid adverse effects. Drug is available only in oral
forms.
Adults
Anxiety: Usual dose is 30 mg/day PO in divided doses tid; adjust
gradually within the range of 15–60 mg/day; also may be given as a single daily
dose hs with a maximum starting dose of 15 mg. For maintenance, give the
22.5-mg PO tablet in a single daily dose as an alternate form for patients
stabilized on 7.5 mg PO tid; do not use to initiate therapy; the 11.25-mg
tablet may be given as a single daily dose.
Adjunct to antiepileptic
medication: Maximum initial dose is
7.5 mg PO tid. Increase dosage by no more than 7.5 mg every wk, do not exceed
90 mg/day.
Acute alcohol withdrawal: Day 1: 30 mg PO initially, then 30–60 mg in divided doses. Day
2: 45–90 mg PO in divided doses. Day 3: 22.5–45 mg PO in divided doses. Day 4:
15–30 mg PO in divided doses. Thereafter, gradually reduce dose to 7.5–15
mg/day PO, and stop as soon as condition is stable.
Pediatric
Patients
Adjunct to antiepileptic
medication:
·
12 yr: Use adult dosage.
·
9–12 yr: Maximum initial
dose is 7.5 mg PO bid; increase dosage by no more than 7.5 mg every wk, and do
not exceed 60 mg/day.
·
< 9 yr: Not
recommended.
Geriatric
Patients or Patients with Debilitating Disease
Anxiety: Initially, 7.5–15
mg/day PO in divided doses. Adjust as needed and tolerated.
Therapeutic
actions
Exact mechanisms not understood;
benzodiazepines potentiate the effects of GABA, an inhibitory neurotransmitter;
anxiolytic effects occur at doses well below those necessary to cause sedation,
ataxia.
Indications
Management of anxiety disorders
or for short-term relief of symptoms of anxiety
Symptomatic relief of acute
alcohol withdrawal
Adjunctive therapy for partial
seizures
Adverse
effects
Drowsiness, muscular hypotonia,
anterograde amnesia, tremor, GI upsets.
Contraindications
Contraindicated with
hypersensitivity to benzodiazepines; psychoses; acute narrow-angle glaucoma;
shock; coma; acute alcoholic intoxication with depression of vital signs;
pregnancy (risk of congenital malformations, neonatal withdrawal syndrome);
labor and delivery (“floppy infant” syndrome); lactation (infants tend to
become lethargic and lose weight).
Use cautiously with impaired
liver or renal function, debilitation; elderly patients.
Nursing
considerations
CLINICAL ALERT! Name
confusion has occurred between clorazepate and clofibrate; use caution.
Assessment
History: Hypersensitivity to benzodiazepines; psychoses; acute
narrow-angle glaucoma; shock; coma; acute alcoholic intoxication; pregnancy;
lactation; impaired liver or renal function; debilitation
Physical: Skin color, lesions; T; orientation, reflexes, affect,
ophthalmologic examination; P, BP; R, adventitious sounds; liver evaluation,
abdominal examination, bowel sounds, normal output; CBC, LFTs, renal function
tests
Interventions
WARNING: Taper dosage gradually
after long-term therapy, especially in epileptics.
Arrange for patients with
epilepsy to wear medical alert identification, indicating disease and
medication usage.
Teaching
points
·
Take drug exactly as
prescribed; do not stop taking drug (long-term therapy) without consulting your
health care provider.
·
Avoid alcohol,
sleep-inducing, or over-the-counter drugs.
·
Avoid pregnancy while
taking this drug; using barrier contraceptives is advised. If you become
pregnant, do not stop the drug; contact your health care provider.
·
You may experience these
side effects: Drowsiness, dizziness (may be transient; avoid driving a car or
engaging in other dangerous activities); GI upset (take with food); fatigue;
depression; dreams; crying; nervousness; depression, emotional changes;
bed-wetting, urinary incontinence.
·
Report severe dizziness,
weakness, drowsiness that persists, rash or skin lesions, difficulty voiding,
palpitations, swelling in the extremities.